Background The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium
falciparum and has partial protective efficacy against clinical and severe malaria disease in …

Background The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein,
inducing antibodies associated with the prevention of Plasmodium falciparum infection. We …

Objectives Eastern Africa has the highest incidence and mortality rates from cervical cancer
worldwide. It is important to describe the differences among women and their perceived risk …

As human papillomavirus (HPV) vaccines become available in less-developed countries,
understanding women's attitudes towards HPV vaccines can help guide approaches to …

Background Results from a previous phase 3 study showed efficacy of the RTS,S/AS01
vaccine against severe and clinical malaria in children (in 11 sites in Africa) during a 3–4-year …

… Damaris Ogake Ondimu1,&, Gideon Mutie Kikuvi1, Walter None Otieno2 … Walter None
Otieno provided … Walter Otieno, my lecturer Mrs. Caro Musita for their engaged guidance …

ABSTRACT A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan
Africa showed RTS, S/AS01 vaccine efficacy against malaria. We now present in-…

… Walter Otieno supervised the clinical evaluations of the study participants. José A. Stoute
was the principal investigator who designed the study, wrote the protocol and drafted the …

Objective To describe the patient population, priority diseases and outcomes in newborns
admitted <48 hours old to neonatal units in both Kenya and Nigeria. Study design In a network …

Plasmodium falciparum malaria causes 1–2 million deaths per year. Most deaths occur as a
result of complications such as severe anemia and cerebral malaria (CM) (coma). Red cells …